CN105168119A - Compound nasal inhalation gel preparation for treating rhinitis - Google Patents
Compound nasal inhalation gel preparation for treating rhinitis Download PDFInfo
- Publication number
- CN105168119A CN105168119A CN201510709523.8A CN201510709523A CN105168119A CN 105168119 A CN105168119 A CN 105168119A CN 201510709523 A CN201510709523 A CN 201510709523A CN 105168119 A CN105168119 A CN 105168119A
- Authority
- CN
- China
- Prior art keywords
- gel preparation
- compound
- rhinitis
- collunarium
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a compound nasal inhalation gel preparation for treating rhinitis. The compound nasal inhalation gel preparation is prepared from, by weight, 0.2-0.3% of levofloxacin, 0.05-0.75% of hyaluronic acid, 0.025-0.05% of oxymetazoline, 0.8-1.0% of lysozyme, 0.025-0.05% of dexamethasone, 0.6-0.9% of sodium chloride, 8-10% of propylene glycol, 0.8-1.0% of Carbomer, 10-12% of glycerol and the balance purified water. The compound nasal inhalation gel preparation is convenient to use, becomes effective fast, and is free of toxic and side effects. Through scientific matching and reasonable compatibility of medicine materials, the content of effective constituents in the preparation is increased; furthermore, due to the fact that the gel preparation is sprayed onto the nasal mucosa, a unique treatment effect is realized through absorption of capillaries and the nasal mucosa based on the physiological characteristics of the nasal cavity, drug action time is prolonged, and a durable and stable treatment effect is realized.
Description
Technical field
The present invention relates to compound gel preparation technical field, particularly relate to a kind of compound collunarium gel preparation for the treatment of rhinitis.
Background technology
Chronic rhinitis, sinusitis are that one causes hypertrophic inferior turbinate hypertrophy with nasal membrane swelling, nasal cavity secretions increase is the chronic inflammatory disease of feature, clinical treatment chronic rhinitis, sinusitis are based on oral drugs and topical application nasal drop, local topical large mainly with the single drug such as ephedrine, naphazoline, or nose such as spray such as glucocorticoid such as application beclometasone, Flixonase etc. is main, medication is single, duration of efficacy is short and can not reach therapeutic effect lastingly, stably.
Invented by Gao Yundong, patent publication No. is that " one treats acute and chronic sinusitis; the compound medicinal formulation of rhinitis and otitis media " of CN1277843A finds that in clinical practice it has following shortcoming: 1. because its pharmacodynamic stability is poor, at short notice effectively can not be lasting; 2. using method allows patient swing back 80 °, and below head, puts a small stool put throw pillow again, and method is too complicated; 3. the time making patient's head swing back is 10 minutes, due to overlong time, patient can be caused to have a headache, the uncomfortable sensation, particularly cervical spondylosis such as dizzy, hypertension, cerebrovascular chronic disease patient, long layback can cause the temporary transient deficiency of brain blood supply; 4. dosage is large, and each medication every side nasal cavity is with one (4ml/ props up), and both sides are 8ml, and to nasal membrane zest by force, and the medication cycle is long, every day 3 times, and being used in conjunction 2 months is a course for the treatment of, and most patients can not accept life-time service.The present invention proposes a kind of compound collunarium gel preparation for the treatment of rhinitis for this reason.
Summary of the invention
Based on the technical problem that background technology exists, the present invention proposes a kind of compound collunarium gel preparation for the treatment of rhinitis.
The present invention proposes a kind of compound collunarium gel preparation for the treatment of rhinitis, comprises following percentage by weight composition:
Levofloxacin 0.2-0.3%
Hyaluronic acid 0.05-0.75%
Oxymetazoline 0.025-0.05%
Lysozyme 0.8-1.0%
Dexamethasone 0.025-0.05%
Sodium chloride 0.6-0.9%
Propylene glycol 8-10%
Carbomer 0.8-1.0%
Glycerol 10-12%
Surplus is purified water.
Preferably, the compound collunarium gel preparation for the treatment of rhinitis comprises following percentage by weight composition:
Levofloxacin 0.24-0.27%
Hyaluronic acid 0.45-0.55%
Oxymetazoline 0.033-0.043%
Lysozyme 0.88-0.93%
Dexamethasone 0.034-0.045%
Sodium chloride 0.72-0.85%
Propylene glycol 8.66-9.45%
Carbomer 0.86-0.96%
Glycerol 10.5-11.6%
Surplus is purified water.
Preferably, the compound collunarium gel preparation for the treatment of rhinitis comprises following percentage by weight composition:
Levofloxacin 0.26%
Hyaluronic acid 0.51%
Oxymetazoline 0.04%
Lysozyme 0.91%
Dexamethasone 0.042%
Sodium chloride 0.79%
Propylene glycol 9.15%
Carbomer 0.92%
Glycerol 11.2%
Surplus is purified water.
Preferably, oxymetazoline can adopt concentration be 0.025% naphazoline substitute.
Preferably, described gel preparation makes nasal drop, drug for treating rhinitis film or rhinitis suppository.
In the present invention, levofloxacin is complete synthesis fluoroquinolone antibacterial agent, can the activity of anti-bacteria DNA gyrase, blocks copying of DNA of bacteria, thus plays bactericidal action, all have powerful antibacterial action to G+.G-bacterium.Hyaluronic acid is a kind of biopolymer mucopolysaccharide.Deeply can organize, blood circulation promoting, improve and organize intermediate supersession and nutrition supply; Can, as vehicle delivery medicine to specific tissue, medicine be made to reach effective treatment; The helical structure of its uniqueness contains a large amount of hydrophilic groups, has very strong moisture-keeping function, makes medicine fully reach nasal membrane tissue, and does not cause dry nasal cavity.Oxymetazoline is alpha-2-adrenoceptor excitomotor, have selectivity highly to shrinking nasal membrane, also have antihistamine effect, this medicine also not easily passs through blood brain barrier simultaneously, there is ephedrine, advantage that naphazoline medicine is intended without comparability, be ideal nasal cavity medicine preparation; Topical application onset is quick, persistent period is long, one day 2 times, relief of symptoms and therapeutic purposes can be reached completely, without obvious toxic-side effects, and after ephedrine, naphazoline collunarium, get final product relief of symptoms, but duration of efficacy is short, after medication 3-4 days, subjective symptoms comparatively before increases the weight of, continuous application can lessen the curative effect, and nasal cavity is drier, easily form a scab.Lysozyme is polysaccharide hydrolase, participate in mycetocyte film mucopolysaccharide to decompose, antiinflammatory, antibacterial, antiviral, antiallergic, edema and minimizing is had to organize transudation, synergism has been share with antibiotic, can accelerate and promote nose ciliary movement, play its distinctive physiological function, what promote nasal cavity disease lapses to healing fast.Dexamethasone can improve the tension force of blood vessel, alleviates hyperemia, reduces the permeability of capillary, and inflammation-inhibiting infiltrates and oozes out, and has antiinflammatory, anti-allergic effects.Sodium chloride plays and regulates isotonic effect.
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present invention proposes, easy to use, instant effect, have no side effect, by the scientific composition of medicine, the application of reasonable compatibility, improve the content of effective ingredient in medicine, and be sprayed on nasal cavity mucosa, according to physiology of the nose feature, by the absorption of blood capillary bronchia mucosal due to gel, play unique curative effect, extend the pharmaceutically-active time, reach lasting, stable therapeutic effect.Prescription of the present invention can also make nasal drop, drug for treating rhinitis film or rhinitis suppository after adjustment substrate adjuvant, and the improvement of dosage form is also all belong within right of the present invention.
This preparation is easy to use, instant effect, formula are simple, scientific and reasonable.Raw material is easy to buy, if can substitute with naphazoline completely without oxymetazoline, its concentration is 0.025%, and state-promulgated pharmacopoeia specifies that the clinical practice concentration of naphazoline nasal drop is 0.1%, and the Drug level 0.025% of this prescription is completely within the scope of normal safe.Because clinical indication is many, also can as the auxiliary treatment of flu.Therefore be highly suitable for basic unit's outpatient service, clinic, community service station promote the use of.There are good economic results in society.
Detailed description of the invention
Below in conjunction with specific embodiment, further explanation is done to the present invention.
Embodiment 1
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present embodiment proposes, comprises following percentage by weight composition: levofloxacin: 0.2%; Hyaluronic acid: 0.05%; Oxymetazoline: 0.025%; Lysozyme: 0.8%; Dexamethasone: 0.025%; Sodium chloride: 0.6%; Propylene glycol: 8%; Carbomer: 0.8%; Glycerol: 10%; Surplus is purified water.
Embodiment 2
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present embodiment proposes, comprises following percentage by weight composition: levofloxacin: 0.24%; Hyaluronic acid: 0.45%; Oxymetazoline: 0.033%; Lysozyme: 0.88%; Dexamethasone: 0.034%; Sodium chloride: 0.72%; Propylene glycol: 8.66%; Carbomer: 0.86%; Glycerol: 10.5%; Surplus is purified water.
Embodiment 3
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present embodiment proposes, comprises following percentage by weight composition: levofloxacin: 0.26%; Hyaluronic acid: 0.51%; Oxymetazoline: 0.04%; Lysozyme: 0.91%; Dexamethasone: 0.042%; Sodium chloride: 0.79%; Propylene glycol: 9.15%; Carbomer: 0.92%; Glycerol: 11.2%; Surplus is purified water.
Embodiment 4
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present embodiment proposes, comprises following percentage by weight composition: levofloxacin: 0.27%; Hyaluronic acid: 0.55%; Oxymetazoline: 0.043%; Lysozyme: 0.93%; Dexamethasone: 0.045%; Sodium chloride: 0.85%; Propylene glycol: 9.45%; Carbomer: 0.96%; Glycerol: 11.6%; Surplus is purified water.
Embodiment 5
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present embodiment proposes, comprises following percentage by weight composition: levofloxacin: 0.3%; Hyaluronic acid: 0.75%; Oxymetazoline: 0.05%; Lysozyme: 1.0%; Dexamethasone: 0.05%; Sodium chloride: 0.9%; Propylene glycol: 10%; Carbomer: 1.0%; Glycerol: 12%; Surplus is purified water.
Embodiment 6
A kind of compound collunarium gel preparation for the treatment of rhinitis that the present embodiment proposes, comprises following composition: levofloxacin 2g, hyaluronic acid 0.5g, oxymetazoline 0.25g, lysozyme 10g, dexamethasone 0.25g, sodium chloride 9g, propylene glycol 100g, carbomer 10g, glycerol 100g, purified water 1000g.
Gel preparation proposed by the invention has antiinflammatory, antibacterial effect, promotes the reparation of bronchia mucosal, increases the immunologic function of nasal cavity, nasal sinuses, reaches therapeutic effect.Mainly be applicable to the symptom such as nasal obstruction, watery nasal discharge, rhinocnesmus, sneeze, headache, dizziness that acute and chronic rhinitis, sinusitis, allergic rhinitis, nasal polyp, hypertrophic inferior turbinate etc. cause.
Using method of the present invention: after patient gets and lies on the back and hang one's head, by medicinal liquid inside nasal cavity lateral border, nasal vestibule cartilago alaris major, gently medicinal liquid is instilled nasal cavity, each 5-6 that drips drips, drip off rear have gentle hands and push away nose, light pressure wing of nose both sides a moments, and softly or read silently " open, open, open ", by the slight vibration of cavum nasopharyngeum, make medicinal liquid fully reach nasal cavity, nasal sinuses, play therapeutic effect.Every day 2 times, 7 days courses for the treatment of, general 2-3 the course for the treatment of cures.
Clinical effectiveness of the present invention: because this drug effect is rapid, determined curative effect is stablized, non-stimulated, have no side effect, the over thousands of routine chronic rhinitis of the triennium internal therapy of clinical practice, the patient of sinusitis, all can clinical cure be reached.Treating both the principal and secondary aspects of a disease is ideal nasal cavity topical application nasal drop.
Side effect of the present invention and untoward reaction: a large amount of patient cases of application, only quite minority other patient has slight burn feeling at the application initial stage, excitement, and medication can disappear after 2 days.All the other patients application has no the generation of other untoward reaction.
Toxicity of the present invention and pharmacological evaluation: pharmacological tests shows, this medicine has antibacterial, antiinflammatory, antianaphylactic effect, and toxicity study experiment shows, its median lethal dose(LD 50) is equivalent to 600 times of normal clinical consumption, and the clinical practice of I phase is safe and reliable stable.
The above; be only the present invention's preferably detailed description of the invention; but protection scope of the present invention is not limited thereto; anyly be familiar with those skilled in the art in the technical scope that the present invention discloses; be equal to according to technical scheme of the present invention and inventive concept thereof and replace or change, all should be encompassed within protection scope of the present invention.
Claims (5)
1. treat a compound collunarium gel preparation for rhinitis, it is characterized in that, comprise following percentage by weight composition:
Levofloxacin 0.2-0.3%
Hyaluronic acid 0.05-0.75%
Oxymetazoline 0.025-0.05%
Lysozyme 0.8-1.0%
Dexamethasone 0.025-0.05%
Sodium chloride 0.6-0.9%
Propylene glycol 8-10%
Carbomer 0.8-1.0%
Glycerol 10-12%
Surplus is purified water.
2. the compound collunarium gel preparation for the treatment of rhinitis according to claim 1, is characterized in that, the compound collunarium gel preparation for the treatment of rhinitis comprises following percentage by weight composition:
Levofloxacin 0.24-0.27%
Hyaluronic acid 0.45-0.55%
Oxymetazoline 0.033-0.043%
Lysozyme 0.88-0.93%
Dexamethasone 0.034-0.045%
Sodium chloride 0.72-0.85%
Propylene glycol 8.66-9.45%
Carbomer 0.86-0.96%
Glycerol 10.5-11.6%
Surplus is purified water.
3. the compound collunarium gel preparation for the treatment of rhinitis according to claim 1 and 2, is characterized in that, the compound collunarium gel preparation for the treatment of rhinitis comprises following percentage by weight composition:
Levofloxacin 0.26%
Hyaluronic acid 0.51%
Oxymetazoline 0.04%
Lysozyme 0.91%
Dexamethasone 0.042%
Sodium chloride 0.79%
Propylene glycol 9.15%
Carbomer 0.92%
Glycerol 11.2%
Surplus is purified water.
4. the compound collunarium gel preparation of the treatment rhinitis according to claim 1-3, is characterized in that, oxymetazoline can adopt concentration be 0.025% naphazoline substitute.
5. the compound collunarium gel preparation of the treatment rhinitis according to claim 1-3, is characterized in that, described gel preparation makes nasal drop, drug for treating rhinitis film or rhinitis suppository.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510709523.8A CN105168119A (en) | 2015-10-28 | 2015-10-28 | Compound nasal inhalation gel preparation for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510709523.8A CN105168119A (en) | 2015-10-28 | 2015-10-28 | Compound nasal inhalation gel preparation for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105168119A true CN105168119A (en) | 2015-12-23 |
Family
ID=54890901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510709523.8A Pending CN105168119A (en) | 2015-10-28 | 2015-10-28 | Compound nasal inhalation gel preparation for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168119A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107441482A (en) * | 2017-09-28 | 2017-12-08 | 佛山市南海东方澳龙制药有限公司 | A kind of cow breast injection gel and preparation method thereof |
| CN107753936A (en) * | 2016-08-19 | 2018-03-06 | 昆明倍健生物科技有限公司 | A kind of preparation for treating rhinitis and preparation method thereof |
| CN110478354A (en) * | 2019-08-22 | 2019-11-22 | 马鹏飞 | A kind of sustained release pharmaceutical composition that treating allergic rhinitis, preparation method and application |
| CN111135141A (en) * | 2020-01-20 | 2020-05-12 | 蓝佳堂生物医药（福建）有限公司 | Preparation method of composite hydrogel for nasal cavity |
| IT202100005051A1 (en) * | 2021-03-04 | 2022-09-04 | Ape8 S R L | MEDICAL COMPOSITION FOR INHALATION |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1208617A (en) * | 1998-08-30 | 1999-02-24 | 刘文通 | Nose drops |
| CN101573118A (en) * | 2006-10-12 | 2009-11-04 | 杏林制药株式会社 | Aqueous liquid preparation comprising gatifloxacin |
| CN103735496A (en) * | 2014-02-14 | 2014-04-23 | 孙迎东 | Compound nasal gel for treating allergic rhinitis and preparing method thereof |
| CN104546716A (en) * | 2014-01-14 | 2015-04-29 | 中国药科大学 | Nasal temperature-sensitive type hydrogel spray |
-
2015
- 2015-10-28 CN CN201510709523.8A patent/CN105168119A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1208617A (en) * | 1998-08-30 | 1999-02-24 | 刘文通 | Nose drops |
| CN101573118A (en) * | 2006-10-12 | 2009-11-04 | 杏林制药株式会社 | Aqueous liquid preparation comprising gatifloxacin |
| CN104546716A (en) * | 2014-01-14 | 2015-04-29 | 中国药科大学 | Nasal temperature-sensitive type hydrogel spray |
| CN103735496A (en) * | 2014-02-14 | 2014-04-23 | 孙迎东 | Compound nasal gel for treating allergic rhinitis and preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李小兵: "复方氧氟沙星滴鼻液的制备及临床应用", 《中国药师》 * |
| 黄峻 等: "《临床药物手册》", 31 January 2015, 上海科学技术出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107753936A (en) * | 2016-08-19 | 2018-03-06 | 昆明倍健生物科技有限公司 | A kind of preparation for treating rhinitis and preparation method thereof |
| CN107441482A (en) * | 2017-09-28 | 2017-12-08 | 佛山市南海东方澳龙制药有限公司 | A kind of cow breast injection gel and preparation method thereof |
| CN110478354A (en) * | 2019-08-22 | 2019-11-22 | 马鹏飞 | A kind of sustained release pharmaceutical composition that treating allergic rhinitis, preparation method and application |
| CN111135141A (en) * | 2020-01-20 | 2020-05-12 | 蓝佳堂生物医药（福建）有限公司 | Preparation method of composite hydrogel for nasal cavity |
| IT202100005051A1 (en) * | 2021-03-04 | 2022-09-04 | Ape8 S R L | MEDICAL COMPOSITION FOR INHALATION |
| WO2022185242A1 (en) * | 2021-03-04 | 2022-09-09 | Ape8 S.R.L. | Medical composition for inhalation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105168119A (en) | Compound nasal inhalation gel preparation for treating rhinitis | |
| JPH11511758A (en) | Intranasal spray containing nasal steroids and antihistamines | |
| DK2303287T3 (en) | Antiallergic marine biopolymers | |
| WO2007022541A3 (en) | Method of treating dry eye disease with non-drying antihistamines | |
| JPH0269413A (en) | Treatment of allergic rhinitis | |
| JP5584713B2 (en) | Nasal drops based on sodium azulenesulfonate | |
| CN105687640A (en) | Medicine for treating surgical wounds and preparation method thereof | |
| CN108366991B (en) | Synergistic compound of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof for the treatment and/or prevention of dryness and irritation of mucous membranes, and related pharmaceutical formulations | |
| KR102199560B1 (en) | Composition and method for treating sinus mucosa disease with nicotinic acetylcholine receptor agonist | |
| JPH10513454A (en) | Therapeutic method using rubidium ion and its preparation | |
| JP5930332B2 (en) | Use of sprayable compositions comprising ambroxol | |
| CN112587510B (en) | External nerve-soothing and sleep-aiding preparation applied to Shenque acupoint | |
| CN102370777A (en) | Medicament for treating non-ulcerated chilblains | |
| CN1251710C (en) | Quick-effective externally used medicine for treating traumatic injury and its preparing method | |
| Kumar et al. | Vaman Karma in Yauvan Pidika (Mukhdushika) wsr to Acne Vulgaris: A Case Study | |
| CN101176790B (en) | Percutaneous absorption fortifier | |
| RU2470667C2 (en) | Intranasal agent possessing inflammatory and immunostimulating action | |
| CN102579482A (en) | Medicinal composition for treating allergic rhinitis | |
| RU2186566C2 (en) | Method for treating rhinitis | |
| CN103536688A (en) | Anti-allergic inflammation drop | |
| BR112018067718B1 (en) | COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE NASAL AND PARANASAL MUCOSA WITH NICOTINUM ACETYLCHOLINE RECEPTOR AGONISTS | |
| KR20140138640A (en) | Therapeutic compositions for intranasal administration of zolpidem | |
| CN108403991A (en) | Pill of Eight Treasures treats the purposes of face acnes and its pharmaceutical composition of pill of Eight Treasures | |
| NZ787061A (en) | Compositions and methods for treating nasal and paranasal mucosa diseases with | |
| UA47594U (en) | Composition for treating and preventing diseases of respiratory tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151223 |